Pfizer Inc. $PFE Shares Sold by Sarasin & Partners LLP

Sarasin & Partners LLP lowered its stake in Pfizer Inc. (NYSE:PFE) by 2.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,419,406 shares of the biopharmaceutical company’s stock after selling 35,092 shares during the quarter. Sarasin & Partners LLP’s holdings in Pfizer were worth $33,853,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares during the period. Geode Capital Management LLC boosted its stake in shares of Pfizer by 1.4% in the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after purchasing an additional 1,820,634 shares during the period. Norges Bank acquired a new position in Pfizer in the 2nd quarter worth $2,270,157,000. Amundi boosted its position in Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after buying an additional 15,758,846 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Pfizer by 2.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after acquiring an additional 1,135,457 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE opened at $25.19 on Friday. The firm has a fifty day moving average of $25.10 and a 200-day moving average of $24.84. The company has a market cap of $143.22 billion, a price-to-earnings ratio of 14.65 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s payout ratio is currently 100.00%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Scotiabank reaffirmed a Buy on PFE, signaling continued analyst conviction from some firms despite the weak outlook. Scotiabank Reaffirms Buy
• Positive Sentiment: Pfizer moved to strengthen its obesity pipeline by licensing a weight-loss drug from Fosun, a strategic push into a high-growth market that could drive medium-term revenue upside if commercialization succeeds. Pfizer licenses weight-loss drug from Fosun
• Positive Sentiment: New liver cancer trial update suggests potential longer-term oncology upside, adding to the narrative that successful Phase III execution could materially re-rate the stock over time. Pfizer’s New Liver Cancer Trial
• Neutral Sentiment: Analysts and industry write-ups (MarketBeat, Benzinga comparisons, and Motley Fool pieces) are weighing PFE versus peers (Merck, Eli Lilly) — useful context but varied conclusions; these pieces emphasize that Pfizer’s future returns hinge on pipeline execution and commercial recovery. Better Buy in 2026: Pfizer or Merck?
• Neutral Sentiment: One analyst summary notes PFE looks materially undervalued with a high forward yield, but warns upside is conditional on successful late‑stage trials and commercialization. This frames PFE as a yield/turnaround play rather than immediate growth. Pfizer Isn’t Dead Money
• Negative Sentiment: Pfizer issued a muted 2026 outlook and trimmed profit guidance, citing lower COVID sales and patent/exclusivity pressures; that guidance and the revenue/profit trims are the primary reasons shares fell today. Pfizer Down After Muted 2026 Outlook
• Negative Sentiment: Following the outlook, some brokers cut or softened ratings (average brokerage rating now around Hold), and the stock has taken analyst downgrades and short‑term selling pressure. Average Rating of Hold from Brokerages
• Negative Sentiment: High-profile commentary (Jim Cramer) highlighting management struggles adds to negative sentiment and short-term headline risk after the guidance release. Jim Cramer: CEO Struggling

Wall Street Analyst Weigh In

A number of brokerages recently commented on PFE. HSBC reissued a “buy” rating and issued a $29.00 price target on shares of Pfizer in a report on Wednesday, December 10th. Wolfe Research set a $24.00 target price on Pfizer and gave the company an “underperform” rating in a research note on Wednesday. Scotiabank initiated coverage on shares of Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target for the company. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. Finally, Citigroup assumed coverage on shares of Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.06.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.